These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
611 related items for PubMed ID: 18300872
1. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872 [Abstract] [Full Text] [Related]
2. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Circulation; 2009 Jan 27; 119(3):417-25. PubMed ID: 19139391 [Abstract] [Full Text] [Related]
3. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, Keefe DL. J Renin Angiotensin Aldosterone Syst; 2009 Sep 27; 10(3):157-67. PubMed ID: 19617271 [Abstract] [Full Text] [Related]
4. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, Fang H, Satlin A. J Renin Angiotensin Aldosterone Syst; 2007 Dec 27; 8(4):190-8. PubMed ID: 18205098 [Abstract] [Full Text] [Related]
5. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. J Hypertens; 2007 Jan 27; 25(1):217-26. PubMed ID: 17143194 [Abstract] [Full Text] [Related]
6. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Puig JG, Schunkert H, Taylor AA, Boye S, Jin J, Keefe DL. Clin Ther; 2009 Dec 27; 31(12):2839-50. PubMed ID: 20110023 [Abstract] [Full Text] [Related]
7. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Andersen K, Weinberger MH, Egan B, Constance CM, Wright M, Lukashevich V, Keefe DL. Cardiovasc Ther; 2010 Dec 27; 28(6):344-9. PubMed ID: 20406241 [Abstract] [Full Text] [Related]
8. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Verdecchia P, Calvo C, Möckel V, Keeling L, Satlin A. Blood Press; 2007 Dec 27; 16(6):381-91. PubMed ID: 18058456 [Abstract] [Full Text] [Related]
9. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Am J Hypertens; 2007 Jan 27; 20(1):11-20. PubMed ID: 17198906 [Abstract] [Full Text] [Related]
12. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL. Am J Cardiovasc Drugs; 2011 Oct 01; 11(5):327-33. PubMed ID: 21846154 [Abstract] [Full Text] [Related]
13. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. J Hum Hypertens; 2007 Oct 01; 21(10):780-7. PubMed ID: 17541390 [Abstract] [Full Text] [Related]
14. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. J Hypertens; 2009 Jul 01; 27(7):1493-501. PubMed ID: 19444142 [Abstract] [Full Text] [Related]
15. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. J Hum Hypertens; 2010 Sep 01; 24(9):600-8. PubMed ID: 20033075 [Abstract] [Full Text] [Related]
16. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh CM, Bizot MN, Denouel J, Dieterich HA, Dole WP. Int J Clin Pract; 2006 Nov 01; 60(11):1343-56. PubMed ID: 17073832 [Abstract] [Full Text] [Related]
17. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Adv Ther; 2008 Dec 01; 25(12):1288-302. PubMed ID: 19066757 [Abstract] [Full Text] [Related]
18. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. Lacourcière Y, Taddei S, Konis G, Fang H, Severin T, Zhang J. J Hypertens; 2012 Oct 01; 30(10):2047-55. PubMed ID: 22828090 [Abstract] [Full Text] [Related]